RxDoctor Payments Data

John Richardson, MD

Physical Medicine & Rehabilitation · Birmingham, ALNPI 1558706986

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 37.3% of the total. Reporting peaked in 2020 at $269 and has fallen 77.2% since, to $61 in 2025.

$696in general payments, 2019–2025

Across 29 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$260
  • Pfizer$180
  • Medtronic$108
  • Baxter Healthcare$82
  • Avanir Pharmaceuticals, Inc.$32
  • Livanova USA, Inc.$20
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$696 in reported general payments places this provider in the 55th percentile of 104 physical medicine & rehabilitation providers in Alabama.

See all physical medicine & rehabilitation providers in Alabama

Medicare billing

Part B allowed, 2024
$209,359
Medicare patients
417
Services billed
2,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$35,479
FarxigaDapagliflozin Propanediol11$4,033
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,394
Atorvastatin Calcium94$606
Gabapentin55$558
Potassium Chloride40$505
Pantoprazole Sodium76$468
Duloxetine Hcl26$383
Pregabalin12$373
Metoprolol Succinate30$311
Levothyroxine Sodium53$302
Tamsulosin Hcl37$220
Amlodipine Besylate67$215
Buspirone Hcl14$187
Losartan Potassium33$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$180$35,47966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 104 physical medicine & rehabilitation providers in Alabama.

Other physical medicine & rehabilitation in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →